ALL - Acute lymphoblastic leukemia

  1. A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
    Primary researcher: Kimmo Porkka

  2. An observational study of blinatumomab safety, effectiveness, utilisation and treatment practices.
    Primary researcher: Ulla Wartiovaara-Kautto

 Contact information tel. +358 50 427 0680